Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
The Journal of Antimicrobial Chemotherapy|June 25, 1999
Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non-compartmental pharmacokineticsA H Groll, C E Gonzalez, N Giri, et al.
Antimicrobial Agents and Chemotherapy|March 18, 2000
Compartmental pharmacokinetics and tissue distribution of multilamellar liposomal nystatin in rabbitsA H Groll, D Mickiene, K Werner, et al.
Antimicrobial Agents and Chemotherapy|February 13, 2001
Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasisV Petraitis, R Petraitiene, A H Groll, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1994
Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasmaJ Berenguer, N M Ali, M C Allende, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1995
Pharmacokinetics of orally administered carboxyamido-triazole, an inhibitor of calcium-mediated signal transductionW D Figg, K A Cole, E Reed, et al.
Pharmacotherapy|December 28, 1999
Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction studyJ Falloon, S Sargent, S C Piscitelli, et al.
The Journal of Infectious Diseases|April 1, 1997
Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected personsR T Davey, D G Chaitt, S C Piscitelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 1998
Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancerV K Kasturi, M P Dearing, S C Piscitelli, et al.
The Journal of Infectious Diseases|July 1, 1996
Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1R E Walker, K M Spooner, G Kelly, et al.
The Journal of Infectious Diseases|April 1, 1996
Combination therapy with didanosine and interferon-alpha in human immunodeficiency virus-infected patients: results of a phase I/II trialJ A Kovacs, C Bechtel, R T Davey, et al.
Pageof 8